Eli Lilly and Company (NYSE:LLY) is InTrack Investment Management Inc’s 6th Largest Position

InTrack Investment Management Inc reduced its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 15.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,505 shares of the company’s stock after selling 643 shares during the quarter. Eli Lilly and Company accounts for 2.2% of InTrack Investment Management Inc’s investment portfolio, making the stock its 6th biggest holding. InTrack Investment Management Inc’s holdings in Eli Lilly and Company were worth $3,105,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares in the last quarter. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 6.0% during the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares in the last quarter. Capital International Investors grew its position in Eli Lilly and Company by 5.1% during the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after buying an additional 335,560 shares during the period. Fisher Asset Management LLC increased its holdings in Eli Lilly and Company by 1.9% in the fourth quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock valued at $2,647,675,000 after buying an additional 85,015 shares in the last quarter. Finally, GQG Partners LLC lifted its position in shares of Eli Lilly and Company by 20.2% during the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after acquiring an additional 648,094 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.3 %

Shares of NYSE:LLY opened at $932.06 on Friday. The stock’s 50-day moving average price is $910.84 and its two-hundred day moving average price is $852.86. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm has a market cap of $885.83 billion, a price-to-earnings ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on LLY shares. Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday. Finally, Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $979.29.

Read Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

• Five stocks we like better than Eli Lilly and Company
• High Dividend REITs: Are They an Ideal Way to Diversify?
• 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
• How to Find Undervalued Stocks
• China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
• What Are Some of the Best Large-Cap Stocks to Buy?
• MarketBeat Week in Review – 10/7 – 10/11

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).